Dealing with our “In-vironment”: New Aspects in IBD Pathogenesis and Therapy

May 4 – 5, 2012
Congress Center Basel
Switzerland

Program
12 credit hours (CME) have been awarded for the Falk Symposium 183 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

Our understanding of the pathogenesis of inflammatory bowel disease has dramatically changed during the last years. The focus of research has shifted from adaptive immunity to genetic risk factors and now to disturbances in innate immunity and the interactions of the mucosal immune system with the content of the gut – our “invironment”. The invironment is a term introduced by Michael Mayerfeld Bell in his book „An Invitation to Environmental Sociology.“ He describes it as the “human body, which is continuously interacting with the environment”. He points to the fact that eating and drinking are special ways for humans to interact with their environment.

The groundbreaking insights gained in the last years indicate that the genetic factors contribute only less than 50% to the risk to develop IBD. Environmental factors may trigger or even cause the disease. Those factors mediate their effects via uptake into the human body. They may change the composition of our microbiome making it more pro-inflammatory or aggressive. Other factors may directly act on the intestinal barrier function.

Our therapeutic approaches still mainly focus on regulating adaptive immunity. Only recently the barrier function of the gut mucosa and the defense function of the innate immune system have come into focus. The meeting therefore will highlight recent discoveries that may change our future treatment strategies. It seems to be promising to intervene early in the pathogenic process, we only start to understand at present.

In our two day meeting which will offer you latest insights from renowned experts the first day will be reserved for the newest data on pathogenic factors. Genetic risk factors, microbiome changes, helminth effects, barrier functions of the mucosa and environmental risk factors will be highlighted. The second day is focussed on newest developments in IBD therapy. We will discuss the value of new diagnostic markers, the options to change environmental influences, the advantages and disadvantages of classical immunosuppression and the value of new concepts such as mucosal healing and deep remission.

We hope that the program and the outstanding faculty will attract you interest and look forward to meet you in Basel in May 2012.

G. Rogler  J. F. Colombel
C. Beglinger  P. Michetti
Dealing with our „In-vironment”: New Aspects in IBD Pathogenesis and Therapy

Congress Center Basel
Switzerland

**Registration:**
Thursday, May 3, 2012
8.00 – 16.30
at the congress office

**Scientific Organization:**
G. Rogler, Zurich (Switzerland)
C. Beglinger, Basel (Switzerland)
J. - F. Colombel, Lille (France)
P. Michetti, Lausanne (Switzerland)

**Information:**
Prof. Dr. Dr. Gerhard Rogler
Universitätsspital Zürich
Klinik für Gastroenterologie & Hepatologie
Rämistrasse 100
8091 Zurich
Switzerland
Telephone: +41(0)44/255 95 19
Telefax: +41(0)44/255 94 97
E-mail: gerhard.rogler@usz.ch

**Official Language:**
English

**Posters:**
For details see page 10

**Congress Venue:**
Congress Center Basel
Messeplatz 21
4058 Basel
Switzerland
Friday, May 4, 2012

8.00 Opening remarks

**Session I**
**Genetic risk factors in IBD:**
Impaired control of the “in-vironment”?  
*Chair:* D. P. Jewell, Oxford; S. Schreiber, Kiel

8.10 Risk genes in Crohn’s disease: What are the most important pathways affected?  
A. Franke, Kiel

8.35 Microflora and genetic risk – Does this explain the Trigger Factor?  
S. Schreiber, Kiel

9.00 The “promise of epigenetics”: Will it deliver new insights?  
S. Gay, Zurich

9.25 **State-of-the-Art Lecture I**  
Genes and “in-vironment”: How will our concepts on the pathophysiology of IBD develop in the future?  
C. Fiocchi, Cleveland

9.50 Coffee break with poster session

**Session II**
**IBD: The “in-vironment” out of control?**  
*Chair:* C. Fiocchi, Cleveland; R. B. Sartor, Chapel Hill

10.20 IBD: A defensin deficiency?  
J. Wehkamp, Stuttgart

10.45 Do bacteria stress the epithelial barrier?  
A. Kaser, Cambridge

11.10 IBD: Dysfunction of autophagy?  
M. Scharl, Zurich

11.35 Helminths and epithelial cells  
J. V. Weinstock, Boston

12.00 Smoking cessation changes the “in-vironment”  
L. Biedermann, Zurich

12.25 Lunch break with poster session

20 minutes lecture 5 minutes discussion
Friday, May 4, 2012

**Session III**
**The epithelial barrier as border to the “in-vironment”**

**Chair:** C. Beglinger, Basel; E. F. Stange, Stuttgart

13.30 **Regeneration of the barrier: The role of stem cells**  
N. F. Shroyer, Cincinnati

13.55 **Novel mechanisms of control of epithelial barrier function**  
S. Danese, Rozzano

14.20 **The leaky epithelium in IBD**  
J.-D. Schulze, Berlin

14.45 **PPARgamma maintains antimicrobial immunity in the colon**  
M. Chamaillard, Lille

15.10 **Coffee break with poster session**

**Session IV**
**Environment and “in-vironment”**

**Chair:** J. Cosnes, Paris; M. H. Vatn, Oslo

15.40 **Why and where to look in the environment in regards to IBD etiology**  
C. N. Bernstein, Winnipeg

16.05 **Does our food (environment) change our gut microbiome (“in-vironment”): Potential role for IBD?**  
P. Lepage, Jouy-en-Josas

16.30 **DAMP’s (danger associated molecular patterns) and IBD: Is there a connection?**  
C. Müller, Bern

16.55 **Microparticles and their impact on intestinal immunity**  
G. Rogler, Zurich

17.20 **State-of-the-Art Lecture II**  
**IBD and “in-vironment”: What have we learned during the last 20 years?**  
R. B. Sartor, Chapel Hill

17.50 **End of afternoon session**

20 minutes lecture 5 minutes discussion
Session V
Treatment decisions made easy:
Do we have the disease markers we need?

**Chair:** M. Fried, Zurich; J. Schölmerich, Frankfurt

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td>Circulating antibodies against bacterial wall products: Are there arguments for early immunosuppression?</td>
<td>F. Rieder</td>
<td>Cleveland</td>
</tr>
<tr>
<td>8.25</td>
<td>Clinical risk factors for complicated disease: How reliable are they?</td>
<td>L. Peyrin-Biroulet</td>
<td>Nancy</td>
</tr>
<tr>
<td>8.50</td>
<td>Treatment decision based on biomarkers</td>
<td>C. Beglinger</td>
<td>Basel</td>
</tr>
<tr>
<td>9.15</td>
<td>Intestinal absorption and vitamin levels: Is there need for a new focus?</td>
<td>S. Vavricka</td>
<td>Zurich</td>
</tr>
</tbody>
</table>

9.40 Coffee break with poster session

Session VI
Changing the “in-vironment” for therapy

**Chair:** P. L. Lakatos, Budapest; G. Rogler, Zurich

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.10</td>
<td>Antibiotics for IBD therapy</td>
<td>H. Lochs</td>
<td>Innsbruck</td>
</tr>
<tr>
<td>10.35</td>
<td>Specific probiotics or “fecal transplantation”?</td>
<td>W. Kruis</td>
<td>Cologne</td>
</tr>
<tr>
<td>11.00</td>
<td>Mucosal protection by phosphatidylcholine</td>
<td>W. Stremmel</td>
<td>Heidelberg</td>
</tr>
<tr>
<td>11.25</td>
<td>Topical therapy</td>
<td>V. Groß</td>
<td>Amberg</td>
</tr>
<tr>
<td>11.50</td>
<td><strong>State-of-the-Art Lecture III</strong> The risks and benefits of early immunosuppression and biological therapy</td>
<td>B. E. Sands</td>
<td>New York</td>
</tr>
</tbody>
</table>

12.20 Lunch break with poster session

20 minutes lecture 5 minutes discussion
### Session VII
**The classical immunosuppression: Overrated or underused?**

**Chair:** P. Michetti, Lausanne; M. Zeitz, Berlin

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30</td>
<td>Mucosal healing: A new treatment goal or old wine in new skins?</td>
<td>M. Allez</td>
<td>Paris</td>
</tr>
<tr>
<td>14.45</td>
<td>Azathioprine in the post-SONIC era: To combine or not combine – That is the question?</td>
<td>P. Michetti</td>
<td>Lausanne</td>
</tr>
<tr>
<td>15.10</td>
<td>Tacrolimus and cyclosporine</td>
<td>E. F. Stange</td>
<td>Stuttgart</td>
</tr>
<tr>
<td>15.35</td>
<td><strong>Coffee break with poster session</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.10</td>
<td><strong>Presentation of poster prizes</strong></td>
<td>G. Rogler</td>
<td>Zurich</td>
</tr>
</tbody>
</table>

### Session VIII
**Biologicals and beyond**

**Chair:** B. E. Sands, New York; O. H. Nielsen, Herlev

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.20</td>
<td>Biological treatment of Crohn's disease</td>
<td>O. H. Nielsen</td>
<td>Herlev</td>
</tr>
<tr>
<td>16.45</td>
<td>Biological treatment of ulcerative colitis</td>
<td>S. Ghosh</td>
<td>Calgary</td>
</tr>
<tr>
<td>17.10</td>
<td>Stem cell transplantation: The ASTIC trial</td>
<td>C. J. Hawkey</td>
<td>Nottingham</td>
</tr>
<tr>
<td>17.35</td>
<td>Strategies against adhesion molecules</td>
<td>B. G. Feagan</td>
<td>London, ON</td>
</tr>
<tr>
<td>18.00</td>
<td><strong>State-of-the-Art Lecture IV</strong> The future of IBD therapy: Where do we go from here?</td>
<td>W. J. Sandborn</td>
<td>La Jolla</td>
</tr>
<tr>
<td>18.30</td>
<td>Closing remarks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**20 minutes lecture 5 minutes discussion**
Poster Session

Posters will be exhibited on May 4 – 5, 2012, at the Congress Center Basel. The authors will be in attendance during coffee and lunch breaks on both days.

1. Non-invasive evaluation of ulcerative colitis in remission – Correlation with endoscopy
   D. Achitei, E. Gologan, G. Stefanescu, G. Balan (Iasi, RO)

2. Effect of dietary extracts on the Toll-like receptor pathway: Working towards personalized nutrition for inflammatory bowel disease
   N. Ahmed-Nasef, G. Marlow, L.L. Ferguson (Auckland, NZ)

3. Retrospective analysis of microscopic colitis patients: Single center experience
   Z. Akpinar, S. Gunay, S. Vatansever, M. Arabul, S. Ipek, E. Alper, H.S. Akay, B. Unsal (Izmir, TR)

4. Postoperative fistulas on the neo-terminal ileum in Crohn’s disease

5. Azathioprine withdrawal in patients with Crohn’s disease in clinical remission: Results of a randomized prospective trial
   N. Ben Mustapha, S. Karoui, M. Serghini, S. Matri, J. Boubaker, M. Fekih, A. Filali (Tunis, TN)

6. Exclusive perineal Crohn’s disease: Epidemiological and evolutive features
   N. Ben Mustapha, H. Boussorra, M. Serghini, S. Karoui, J. Boubaker, M. Fekih, A. Filali (Tunis, TN)

7. Outcomes of Crohn’s disease asymptomatic strictures on infliximab therapy: Results of a monocentric experience
   N. Ben Mustapha, H. Boussorra, M. Serghini, S. Karoui, J. Boubaker, M. Fekih, A. Filali (Tunis, TN)

8. Serum nitric oxide levels as a marker of inflammation and disease severity in patients with ulcerative colitis: A prospective single center study
   Y. Beyazit, A. Sayilir, S. Torun, B. Suvak, T. Celik, A. Tas (Ankara, TR)

9. Metabonomics of human fecal extracts characterize the gut microbiota in inflammatory bowel disease
   J.T. Bjerrum, Y. Wang, F. Hao, O.H. Nielsen (Herlev, DK; Wuhan, CN)

10. Pulmonary actinomycosis and tuberculosis in a CD patient treated with adalimumab: A case report
    M. Brinar, S. Cukovic-Cavka, M. Crncevic Urek, I. Aleric, Z. Krznaric, B. Vucelic (Zagreb, HR)
11. Tissue-specific overexpression of the transcription factor Nrf2 increases mucosal inflammation upon dextran sulphate sodium treatment
A. Cee, K. Atrott, M. Fried, G. Rogler, I. Frey-Wagner (Zurich, CH)

12. The gene encoding the G protein-coupled receptor 68 (GPR68/OGR1) is regulated by TNF, hypoxia, and low pH in human monocytic cells

13. Functional consequences of G protein-coupled receptor 68 (GPR68/OGR1) overexpression in intestinal epithelial cells

14. Bioequivalence results for a new azathioprine 100 mg tablet
K. Dilger (Freiburg, DE)

15. IL-28 signaling in intestinal epithelial cells leads to a revised mucosal wound healing
H. Dornhoff, K. Fietkau, S.E. Doyle, M.F. Neurath, J. Siebler (Erlangen, DE; Seattle, US)

16. Endothelin-1 inactivating peptidases and adiponectin in mucosa in children with inflammatory bowel disease (IBD)

17. Infliximab and adalimumab modulate apoptosis of lamina propria lymphocytes in patients with Crohn’s disease in Fas-independent pathway


19. Chronic hepatitis C, inflammatory bowel disease and interferon therapy

20. The increasing incidence of inflammatory bowel diseases (IBD) in Nile Delta area of Egypt
M. El-Hamamsy, A. Elfert (Cairo, Tanta, EG)

21. Arthritis as a presenting symptom of subclinical Crohn’s disease
B. Ergül, E. Kocak, S. Köklü (Ankara, TR)

22. Nutrition status of Crohn’s disease patients and risk factors of malnutrition: A prospective study
M. Fekih, L. Kallel, H. Boussorra, N. Ben Mustapha, M. Serghini, J. Boubaker, A. Filali (Tunis, TN)
23. Bone loss in Crohn’s disease and risk factors  
M. Fekih, L. Kallel, H. Boussorra, N. Ben Mustapha, A. Laabidi, M. Serghini,  
M. Feki, J. Boubaker, A. Filali (Tunis, TN)

24. Hyperhomocysteinemia in Crohn’s disease: Frequency and risk factors  
M. Fekih (Tunis, TN)

25. Cutaneous manifestations in inflammatory bowel diseases: Results of a  
cross-sectional study  
M. Fekih, L. Kallel, H. Boussorra, N. Ben Mustapha, S. Matri, M. Serghini,  
A. Mebazaa, A. Ben Osman, J. Boubaker, A. Filali (Tunis, TN)

26. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving  
the colon: A prospective study  
M. Fekih, L. Kallel, H. Boussorra, N. Ben Mustapha, M. Feki, J. Boubaker, A. Filali  
(Tunis, TN)

27. Exogenous heat shock protein gp96 ameliorates CD4+CD62L+ T cell-mediated  
transfer colitis in a mouse model  
(Zurich, CH)

28. Colitis-associated colon cancer is controlled by the IL-6 level and the transcription  
factor NFATc2  
K. Gerlach, H.A. Lehr, A. Nikolaev, T. Gerlach, R. Atreya, S. Rose-John, M.F. Neurath,  
B. Weigmann (Erlangen, Mainz, Kiel, DE; Lausanne, CH)

29. Measurement of iohexol in serum as an alternative to urine test for assessment  
of intestinal permeability in patients with inflammatory bowel diseases  
V. Gerova-Nankova, D. Svinarov, S. Stoynov (Sofia, BG)

30. Duration of intravenous steroid therapy in patients with severe attack of ulcerative  
colitis  
A.O. Golovenko, I.L. Khalif, T.L. Mikhailova, O.V. Golovenko (Moscow, RU)

31. Immunohistochemical assessment of MMP-7 expression in IBD  
K. Guzinska-Ustymowicz, A. Pryczynicz, J. Kisluk, K. Niewiarowska, A. Borsuk,  
M. Gryko, D. Cepowicz, A. Kemona (Bialystok, PL)

32. Can we use fecal calprotectin in the diagnosis of ulcerative colitis among  
Egyptian patients?  
I. Hamza, M. Nasser, S. Tabak, M. Sharaf-Eldin (Tanta, Beni Sueif, Giza, EG)

33. High-dose cyclophosphamide and autologous hematopoietic cell transplantation  
for inflammatory bowel disease – A single center experience  
P. Hasselblatt, K. Drognitz, K. Potthoff, H. Bertz, W. Kruis, C. Schmidt, A. Stallmach,  
J. Finke, W. Kreisel (Freiburg, Cologne, Jena, DE)
34. Non-invasive quantification of volatile metabolites in breath: A potential indicator of inflammatory bowel diseases activity
L. Hrdlicka, K. Dryahina, P. Spanel, M. Bortlik, D. Duricova, N. Machkova, M. Lukas (Prague, CZ)

35. Bid protein expression in ulcerative colitis
J. Kisluk, K. Guzinska-Ustymowicz, A. Pryczynicz, K. Niewiarowska, M. Gryko, D. Cepowicz, A. Borsuk, A. Kemona (Bialystok, PL)

36. The importance of centralization of biological treatment of IBD patients
M. Konecny (Olomouc, CZ)

37. The value of capsule endoscopy in the evaluation of the effectiveness of the treatment of patients with Crohn’s disease
O. Krylova, V. Tichno (Donetsk, UA)

38. The value of capsule endoscopy in the diagnosis of Crohn’s disease
O. Krylova, V. Tichno (Donetsk, UA)

39. Ferric carboxymaltose administration in iron-deficient and anemic pediatric patients with IBD
M. Laass, S. Straub, G. Virgin, T. Cushway (Dresden, Munich, DE; Glattbrugg, CH)

40. The phospholipids sphingomyelin and phosphatidylcholine contrarily affect the integrity of tight and adherens junctions in the murine intestinal mucosa during experimental inflammatory bowel disease
K. Leucht, M. Krebs, A. Fischbeck, P. Benes, H.-U. Humpf, M. Fried, G. Rogler, M. Hausmann (Zurich, CH; Brno, CZ; Münster, D)

41. Knock-out of BCL-2 interacting mediator of cell death (Bim) aggravates chronic DSS-induced colitis
K. Leucht, M. Krebs, M. Fried, G. Rogler, M. Hausmann (Zurich, CH)

42. Pregnancy and newborn outcome of mothers with inflammatory bowel disease exposed to anti-TNFα therapy during pregnancy: Three center study
N. Machkova, M. Bortlik, D. Duricova, E. Bouzkova, L. Hrdlicka, O. Shonova, P. Kohout, M. Lukas (Prague, Ceske Budejovice, CZ)

43. Climate change and the impact of heat waves on infectious gastroenteritis and relapse rates of inflammatory bowel disease
C.N. Manser, M. Paul, G. Rogler, L. Held, T. Frei (Zurich, CH)

44. CAD, a nucleotide synthesis enzyme, inhibits NOD2 antibacterial function in intestinal epithelial cells
45. Maltodextrin (MDX), a ubiquitous dietary additive in Western diets, enhances biofilm formation and adhesiveness of E. coli: A case for the environment altering the „in-vironment”
C. McDonald, K.P. Nickerson (Cleveland, US)

46. Cognitive-behavioral therapy changes the „in-vironment”
A. Mikocka-Walus, J. Andrews (Adelaide, AU)

47. IRF4-/- mice develop higher tumor number and score in the colitis-associated tumor model than wildtype control mice
N. Nalleweg, M. Lohoff, M.F. Neurath, J. Mudter (Erlangen, Marburg, DE)

48. The comparison expression of proapoptotic proteins (Bak and Bax) and anti-apoptotic Bcl-XL protein in inflammatory bowel diseases

49. Further studies on the serum neutrophil gelatinase-associated lipocalin-2 (NGAL) in children with inflammatory bowel disease (IBD)

50. Intestinal neuronal dysplasia as a rare cause of intestinal obstruction: Case report
E. Ozaslan, T. Purnak, S. Sayar (Ankara, TR)

51. Do localization of inflammatory bowel disease predict the hepatobiliary manifestation?

52. Natural course in Crohn’s disease under the conventional therapy

53. A young patient with acute pancreatitis, B hepatitis, dyslipidemia and bloody stools
G. Parlog (Bacau, RO)

54. The role of caspase-8 in inflammatory bowel diseases
A. Pryczynicz, K. Guzinska-Ustymowicz, K. Niewiarowska, J. Kisluk, A. Borsuk, M. Gryko, D. Cepowicz, A. Kemona (Bialystok, PL)

55. The metabolic syndrome in patients with IBD as compared with patients with colorectal cancer
M. Pumnea, E.C. Rezi (Sibiu, RO)

56. Elevated levels of serum angiotensin converting enzyme (ACE) in patients with ulcerative colitis (UC) as a clue for activated renin-angiotensin system (RAS) in inflammatory bowel diseases
T. Purnak, Y. Beyazit, C. Efe, E. Ozaslan, T. Celik, E. Altiparmak (Ankara, TR)
57. A retrospective study comparing the prevalence and characteristics of the inflammatory bowel diseases and colorectal cancer at different age groups of patients from southern Transylvania
E.C. Rezi, M. Pumnea (Sibiu, RO)

58. Molecular effects of the prebiotic «Zacofalk NMX®» in patients with ulcerative colitis
I. Sarvilina (Rostov-on-Don, RU)

59. Plasma thrombin activatable fibrinolysis inhibitor (TAFI) could be a potential indicator of disease activity in ulcerative colitis
A. Sayilir, Y. Beyazit, M. Albayrak, F. Ekiz, T. Celik, B. Suvak, S. Torun, B.T. Demirel (Ankara, TR)

60. Activation of protein tyrosine phosphatase non-receptor type 2 by the polyamine, spermidine, ameliorates IFNγ-induced proinflammatory effects in human THP-1 monocytes
M. Scharl, J. Arikkat, D.F. McCole, G. Rogler (Zurich, CH; La Jolla, US)

61. The role of TNF-α and IL-2 in ulcerative colitis

62. Expression of TNFR1 in colonic epithelium in inflamed mucosa of patients with Crohn’s disease

63. The potential role of nitric oxide system in inflammatory bowel disease associated colorectal carcinogenesis: A meta-analysis
S. Torun, Y. Beyazit, A. Sayilir, B. Suvak (Ankara, TR)

64. Possibility of predicting 5-year outcomes of ulcerative colitis
S. Turcan, V.-T. Dumbrava, R. Tanase, S. Barca (Chisinau, MD)

65. Immunological features of mouth cavity secretion in children with chronic inflammatory bowel disease
O.A. Tutina, E.N. Fedulova, I.V. Mayanskaya, O.V. Fedorova, O.V. Shumilova (Nizhny Novgorod, RU)

66. Predictors of ileostomy effectiveness in complicated Crohn’s disease of the colon
A.V. Vardanyan, U.A. Shelygin, V.N. Kashnikov, K.V. Bolikhov, I.L. Khalif (Moscow, RU)

67. Epidemiology and outcome of microscopic colitis in northeastern Slovenia
M. Vujasinovic, K. Mojskerc, B. Pospihalj (Slovenj Gradec, SI)
68. Central regulatory role of the transcription factor NFATc2 in cyclosporine A treatment in ulcerative colitis
   B. Weigmann, R. Atreya, J. Mudter, H.A. Lehr, M.F. Neurath (Erlangen, DE; Lausanne, CH)

69. Various epithelial markers in patients with ulcerative colitis with or without coexistence of the primary sclerosing cholangitis – Immunohistochemical study
   P. Wohl, P. Wohl, E. Honsova, P. Drastich, D. Kamenar, J. Matous, J. Spicak (Prague, CZ)

70. The influence of vitamin A on the intestinal permeability and a release of cytokines from human in vitro-differentiated macrophages and dendritic cells
   K.A. Wojtal, H. Kropshofer, L. Müller, L. Wolfram, S.R. Vavricka, G. Rogler (Basel, Zurich, CH)

71. Hypoxia changes mRNA expression levels of SLC transporters in human gastrointestinal tract

72. Fc gamma receptors modulate the inhibitory efficacy of infliximab in blocking TNF-mediated responses in blood and intestine of IBD patients
   K.A. Wojtal, G. Rogler, L. Biedermann, P. Frei, M. Fried, S.R. Vavricka (Zurich, CH)

73. Analysis of the incidental diagnosis of inflammatory bowel disease made during the Scottish bowel cancer screening programme
   M.A. Zahid, C.W. Lees, J. Satsangi, C.L. Noble (Balerno, Edinburgh, GB)
List of Speakers, Moderators and Scientific Organizers

Dr. Matthieu Allez  
Hôpital Saint-Louis  
Service de Gastroentérologie  
1 Ave. C. Vellefaux  
75010 Paris  
France  
matthieu.allez@sls.aphp.fr

Prof. Dr. Christoph Beglinger  
Kantonsspital  
Gastroenterologie  
Petersgraben 4  
4031 Basel  
Switzerland  
beglinger@tmr.ch

Dr. Charles N. Bernstein  
University of Manitoba  
Department of Gastroenterology  
804 F-175 McDermot Avenue  
Winnipeg MB R3E 3P4  
Canada  
cbernst@cc.umanitoba.ca

Dr. med. Luc Biedermann  
Universitätsspital Zürich  
Gastroenterologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
luc.biedermann@usz.ch

Dr. Mathias Chamaillard  
INSERM 1  
rue Prof. A. Calmette  
59021 Lille  
France  
mathias.chamaillard@inserm.fr

Prof. Dr. Jean-Frederic Colombel  
Hôpital Claude Huriez  
CHRU Lille  
Gastroenterology & Hepatology  
1, Place de Verdun  
59037 Lille  
France  
jfcolombel@chru-lille.fr

Prof. Dr. Jacques Cosnes  
Hôpital Saint Antoine  
Service de Gastroentérologie & Nutrition du Prof. Gendre  
184, Rue du Faubourg St.-Antoine  
75571 Paris  
France  
jacques.cosnes@sat.ap-hop-paris.fr

Dr. Silvio Danese  
Istituto Clinico Humanitas  
IRCCS in Gastroenterology  
Via Manzoni, 56  
20089 Rozzano  
Italy  
sdanese@hotmail.com

Dr. Brian G. Feagan  
University of Western Ontario  
Robarts Research Institute  
LCTR  
100 Perth Drive  
London ON N6A 5K8  
Canada  
bfeagan@robarts.ca

Claudio Fiocchi, M.D.  
Professor of Medicine  
The Cleveland Clinic Foundation  
Pathobiology / NC 20  
9500 Euclid Avenue  
Cleveland OH 44195  
USA  
fiocchc@ccf.org

Prof. Dr. Andre Franke  
Klinische Molekularbiologie  
Christian-Albrechts-Universität  
Schittenhelmstrasse 12  
24105 Kiel  
Germany  
a.franke@mucosa.de

Prof. Dr. Michael Fried  
Universitätsspital Zürich  
Gastroenterologie/Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
michael.fried@usz.ch
Noah F. Shroyer, Ph.D.
Assistant Professor of Medicine
Cincinnati Children’s Hospital Medical Center
Developmental Biology
3333 Burnet Avenue
Cincinnati OH 45229-3039
USA
noah.shroyer@cchmc.org

Prof. Dr. Eduard F. Stange
Innere Medizin I
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Germany
eduard.stange@rbk.de

Prof. Dr. Wolfgang Stremmel
Innere Medizin IV
Universitätsklinikum Heidelberg
Im Neuenheimer Feld 410
69120 Heidelberg
Germany
wolfgang_stremmel@med.uni-heidelberg.de

Prof. Dr. Morten H. Vatn
University of Oslo
Rikshospitalet
Medical Clinic of Gastroenterology
0027 Oslo
Norway
m.h.vatn@medisin.uio.no

PD Dr. Stephan Vavricka
Stadtpital Triemli
Dep. of Gastroenterology & Hepatology
Birmensdorferstr. 497
8063 Zurich
Switzerland
stephan.vavricka@triemli.stzh.ch

PD Dr. Jan Wehkamp
Innere Medizin I
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Germany
jan.wehkamp@ikp-stuttgart.de

Joel V. Weinstock, M.D.
Professor of Medicine
Tufts-New England Medical Center
Box 233
750 Washington Street
Boston MA 02111
USA
jweinstock2@tufts-nemc.org

Prof. Dr. Martin Zeitz
Gastroenterologie
Charité Universitätsmedizin
Campus Benjamin Franklin (CBF)
Hindenburgdamm 30
12203 Berlin
Germany
martin.zeitz@charite.de
**Congress Office**

**During** the Falk Symposium 183  
Congress Center Basel  
Messeplatz 21  
4058 Basel  
Switzerland  
Telephone: +49(0)175/77 95 327

**Opening Hours:**
- Wednesday, May 2, 2012, 16.00 – 21.00 h
- Thursday, May 3, 2012, 8.00 – 16.30 h
- Friday, May 4, 2012, 7.30 – 18.00 h
- Saturday, May 5, 2012, 7.30 – 18.30 h

**Congress Fees**

Scientific program of the Falk Symposium 183  
Students and residents  
€ 200,-  
€ 100,-

* * * OR * * *

**Day ticket**  
Students and residents  
€ 120,-  
€ 60,-

**The congress fees include:**
- Welcome Evening on May 2, 2012
- Refreshments during coffee breaks
- Lunch on May 4 and 5, 2012
- A copy of the abstract volume
Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Congress Report

The official congress report of the Falk Symposium 183 “Dealing with our “In-vironment”: New Aspects in IBD Pathogenesis and Therapy” will be published in English in the second half of 2012 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35.- can be placed at the Congress Office during the congress in Basel.

Congress Short Report

The congress short report of the Falk Symposium 183 “Dealing with our “In-vironment”: New Aspects in IBD Pathogenesis and Therapy” will be published by the Falk Foundation e.V. with number FSK 183 in the second half of 2012.

Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

Airport

International Airport Basel
General Information:

FALK FOUNDATION e.V.

Leinenweberstr. 5
79108 Freiburg
Germany

Congress Division
Telephone: +49(0)761/1514-0
Telefax: +49(0)761/1514-359
E-mail: symposia@falkfoundation.de
www.falkfoundation.org